Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ACHIEVE-1 Study Shows Albuferon Non-Inferior To Pegasys; Questions Remain

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

With the March 9 release of the initial results of ACHIEVE-1, the final Phase III trial of Human Genome Sciences/Novartis' pegylated interferon Albuferon, Wall Street analysts have started to question the hepatitis C drug's market value. The trial failed to deliver outstanding efficacy results, and showed some signs of safety problems

You may also be interested in...



Albuferon Dosing Advantage: Less Is More For HCV Patients, Physicians Say

The dosing advantage for Novartis/Human Genome Sciences' follow-on interferon product Albuferon is enough to establish the hepatitis C therapy over Roche's go-to treatment Pegasys, according to a physician panel at the BIO CEO conference - quelling concerns that less frequent dosing might not be enough to get practitioners to switch to the new product

HGS Cuts High Dose Albuferon In Phase III After Increased Pulmonary Events

Lower 900 mcg dose of albinterferon alfa-2b is on track for hepatitis C filing in fall 2009, Human Genome Sciences says.

Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales

Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel